Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson's disease and related disorders. The Company’s multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The Company is also developing platform technologies for alternate ways to deliver protein kinase inhibitors in patients, which includes IkT-001Pro. IkT-001Pro is a prodrug of the anticancer agent imatinib mesylate, to treat stable phase chronic myelogenous leukemia (SP-CML). The Company’s RAMP drug discovery program used imatinib as a template to design and discover a family of novel chemical entities with high potency against c-Abl, leading to IkT-148009.